NasVax Ltd.
This article was originally published in Start Up
Executive Summary
NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family of positively charged polycationic lipids. The technology generates strong adjuvant activity, with the potential for intranasal, intramuscular, or subcutaneous administration. This platform can also be applied to boost the bioactivity of various immunomodulators, such as a broad spectrum of well-established adjuvants and cytokines.
You may also be interested in...
Start-Up Previews (01/08)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "NOTES Companies Sing an Upbeat Tune," and "Solid Support for Flu Vaccine Development." Plus these Start-Ups Across Health Care: Carigent Therapeutics, Cizzle Biotechnology, Genesis Medical Interventional, and ValveXchange.
FluGen Inc.
FluGen aims to improve vaccine manufacturing and ultimately create better, safer, flu vaccines as well as treatments for the viral infections. The start-up is not basing its business model on the possibility of any sort of worldwide pandemic--but its founders' expertise with such matters brings credibility that is bound to be useful in attracting potential partners.
Solid Support for Flu Vaccine Development
Vaccines generally are one of the few areas in pharmaceutical development where government incentives, science, and intellectual property are in alignment to favor commercialization. This is particularly true for flu vaccine, where recent events have drawn the attention of government and Big Pharma. That, plus the advent of new adjuvant technology and innovative manufacturing methods, signals opportunity for new players.